MENU
+Compare
EVO
Stock ticker: NASDAQ
AS OF
Aug 22, 04:59 PM (EDT)
Price
$3.66
Change
+$0.12 (+3.39%)
Capitalization
1.27B

EVO Evotec SE Forecast, Technical & Fundamental Analysis

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations... Show more

EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EVO with price predictions
Aug 21, 2025

EVO's Stochastic Oscillator remains in oversold zone for 11 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EVO as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EVO turned negative on August 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

EVO moved below its 50-day moving average on July 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for EVO moved below the 200-day moving average on August 01, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.312) is normal, around the industry mean (16.049). P/E Ratio (0.000) is within average values for comparable stocks, (73.259). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.834). EVO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (1.427) is also within normal values, averaging (41.180).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EVO is expected to report earnings to fall 65.85% to -4 cents per share on November 05

Evotec SE EVO Stock Earnings Reports
Q3'25
Est.
$-0.05
Q2'25
Missed
by $0.08
Q1'25
Missed
by $0.09
Q4'24
Missed
by $0.09
Q3'24
Est.
$-0.12
The last earnings report on August 13 showed earnings per share of -14 cents, missing the estimate of -6 cents. With 50.42K shares outstanding, the current market capitalization sits at 1.27B.
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Essener Bogen 7
Phone
+49 40560810
Employees
4952
Web
https://www.evotec.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAFSX37.66N/A
N/A
Fidelity Advisor Financials M
PJFCX38.98N/A
N/A
PGIM Jennison Growth C
WEBCX10.55N/A
N/A
TETON Westwood Balanced A
LADVX31.06N/A
N/A
Lord Abbett Developing Growth R6
DSCYX32.83N/A
N/A
BNY Mellon Opportunistic Small Cap Y

EVO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-0.84%
SNDL - EVO
42%
Loosely correlated
+1.36%
LFCR - EVO
29%
Poorly correlated
-0.28%
ACB - EVO
29%
Poorly correlated
+1.27%
ACET - EVO
26%
Poorly correlated
+6.67%
OGI - EVO
25%
Poorly correlated
+4.67%
More

Groups containing EVO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-0.84%
Pharmaceuticals: Generic
industry (225 stocks)
5%
Poorly correlated
+0.70%